9044 POSTER Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy (CRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)72356-5 ◽

2011 ◽

Vol 47 ◽

pp. S605

Author(s):

K. Tanaka ◽

I. Okamoto ◽

N. Yamamoto ◽

Y. Hattori ◽

N. Masuda ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Concurrent Chemoradiotherapy ◽

Locally Advanced ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

AOSOP15 PHASE 2 STUDY COMPARING CISPLATIN/ETOPOSIDE AND WEEKLY PACLITAXEL/CARBOPLATIN REGIMENS WITH CONCURRENT THORACIC RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER

European Journal of Cancer ◽

10.1016/s0959-8049(13)70014-5 ◽

2013 ◽

Vol 49 ◽

pp. S6

Author(s):

J. Liang ◽

W. Wang ◽

G. Ou ◽

Z. Hui ◽

J. Lv ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Weekly Paclitaxel ◽

Phase 2 ◽

Thoracic Radiotherapy ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study

Lung Cancer ◽

10.1016/0169-5002(90)90374-u ◽

1990 ◽

Vol 6 (1-2) ◽

pp. 62

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Final Report ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps9110 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS9110-TPS9110 ◽

Cited By ~ 2

Author(s):

Lecia V. Sequist ◽

Ian Churchill Anderson ◽

Nathan Demars ◽

Enriqueta Felip ◽

Wael A. Harb ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.96 ◽

2016 ◽

Vol 27 ◽

pp. vi452 ◽

Cited By ~ 2

Author(s):

L.V. Sequist ◽

I. Anderson ◽

T.M. Bauer ◽

N. Demars ◽

E. Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969276.793473915 ◽

2013 ◽

Cited By ~ 1

Author(s):

Sam Janes ◽

Laura Succony

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969276.793468807 ◽

2013 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

P82.02 Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1193 ◽

2021 ◽

Vol 16 (3) ◽

pp. S651-S652

Author(s):

J. Beal ◽

D. Gomes ◽

P. Taranto ◽

L. Koch ◽

A.C. Rezende ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Early Stage ◽

Small Cell ◽

Stereotactic Ablative Radiotherapy ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study

Download Full-text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

British Journal of Cancer ◽

10.1038/s41416-021-01356-3 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Qiming Wang ◽

Kai Li ◽

Jianhua Shi ◽

Ying Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.1363 ◽

2019 ◽

Vol 14 (10) ◽

pp. S646 ◽

Cited By ~ 1

Author(s):

C. Ocampo ◽

J. Wu ◽

J. Dey ◽

Z. Sun ◽

M. Motwani ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Cancer Trial ◽

Phase 2 Study ◽

Previously Treated

Download Full-text

Daily Step Counts Predict Outcomes for Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.06.2423 ◽

2019 ◽

Vol 105 (1) ◽

pp. E524-E525

Author(s):

N. Ohri ◽

B. Halmos ◽

W.R. Bodner ◽

H. Cheng ◽

C. Guha ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Concurrent Chemoradiotherapy ◽

Locally Advanced ◽

Small Cell ◽

Daily Step ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text